Table 3 Follow-up data after pregnancy completion in 87 CML patients.
Follow-up data | All patients | Pregnancy outcome | |
|---|---|---|---|
n = 87 | Childbirth | Abortion/miscarriage | |
n = 66 | n = 21 | ||
Living status | |||
Alive, n (%) | 84 (97) | 64 (97) | 20 (95) |
Dead, n (%) | 3 (3) | 2 (3) | 1 (5) |
First line TKI | |||
Imatinib, n(%) | 71 (82) | 51 (77) | 20 (95) |
Dasatinib, n (%) | 9 (10) | 9 (14) | – |
Nilotinib, n (%) | 7 (8) | 6 (9) | 1 (5) |
TKI switch, main reason | |||
Resistance/suboptimal, n (%) | 18 (21) | 14 (21) | 4 (19) |
Intolerance/other, n (%) | 6 (7) | 4 (6) | 2 (10) |
No switch, n (%) | 63 (72) | 48(73) | 15 (71) |
Best overall response, n (%) | |||
MMR | 28 (32) | 22 (33) | 6 (29) |
DMR | 38 (44) | 31 (47) | 7 (33) |
No MMR | 12 (14) | 8 (12) | 4 (19) |
No data | 9 (10) | 5 (8) | 4 (19) |